Patents will soon expire! Dr. Reddy's Laboratories Ltd. Sponsored ADR (RDY.US) will launch its generic version of Semaglutide in 87 countries.

According to reports, Dr. Reddy's Laboratories Ltd. Sponsored ADR (RDY.US) CEO has revealed that the company plans to launch a generic version of Novo Nordisk A/S Sponsored ADR Class B (NVO.US) weight loss drug Wegovy, which contains the active ingredient semaglutide, in 87 countries starting from 2026. As the global patents for the drug expire, the company has initiated registration processes in multiple markets. During a financial report press conference, CEO Erez Israeli referred to this plan as a significant milestone. It is reported that Wegovy was recently launched in India by Novo Nordisk A/S Sponsored ADR Class B, with treatment costs starting at $50 for three doses per week. The generic version of Dr. Reddy's Laboratories Ltd. Sponsored ADR will first enter markets such as Canada, Brazil, and India. Israeli emphasized that the company will also proceed with the launch in countries where Novo Nordisk A/S Sponsored ADR Class B does not have patent protection. This marks Dr. Reddy's Laboratories Ltd. Sponsored ADR's official entry into the GLP-1 drug market, with plans to introduce up to 26 different GLP-1 therapies in the next decade as more patents expire. Israeli pointed out that the drug has strong commercial prospects, with the generic version of semaglutide expected to bring in hundreds of millions of dollars in incremental revenue. M.V. Ramana, CEO of the company's brand marketing department, stated that a tiered pricing strategy will be implemented based on market characteristics in each region to enhance the accessibility of the drug.